Sterile Fill-Finish & 506(e) Outsourcing Facility For Epi Pen, GLP1 and Diabetes Biologics

 Accelerate Delivery and Scale with MayMag Biologics—the premier biologics drug delivery device contract manufacturer, insulin pen OEM supplier, and elite biopharmaceutical parenteral delivery device supplier. Headquartered in Dallas, Texas, with dual cGMP-certified facilities in Dallas and Garland, MayMag Biologics is a USA-based CMO insulin manufacturing partner and cGMP contract development and manufacturing organization (CDMO) built to help sponsors capture global insulin market share and lower global healthcare costs.

We bridge the gap between complex drug substance synthesis and commercial-scale device assembly. As your recombinant insulin API supplier and autoinjector CDMO manufacturing partner, we specialize in large-scale biologics manufacturing and large-scale recombinant protein production targeting FDA approval for interchangeable biosimilar insulin. Our expanded CDMO sterile fill-finish services support biosimilar insulins—including Icodec, Degludec, Glargine, Detemir, and Aspart—in auto-pens and vials, alongside API insulin autopen combination drug production.

End-to-End Biologics & Combination Product Expertise:

  • GLP-1 & Peptide Manufacturing: Premier GLP-1 peptide pen injector contract manufacturing and GLP-1 pen injector supplier services backed by in-house solid-phase peptide synthesis (SPPS) for GLP-1 agonists, tirzepatide and semaglutide analogs, and GLP-1/GIP dual agonists.

  • Custom Device Engineering & Cleanroom Assembly: Recognized as the No. 5 leading insulin self-injection device OEM and 3 mL cartridge insulin delivery pen manufacturer with USFDA 506(e) registration. From custom pen injector device development to ISO 13485 cleanroom device assembly services and commercial-scale insulin device manufacturing, we supply high-volume autoinjectors, epinephrine auto-injectors, rheumatoid arthritis autoinjectors, prefilled syringes, and MDI/DPI inhalation therapeutics.

  • Sterile Fill-Finish & 506(e) Outsourcing: Operating under direct FDA oversight as a DQSA-registered 506(e) outsourcing facility—distinct from traditional state-regulated compounding pharmacies—we execute 21 CFR 4 combination product contract manufacturing, Annex 1-compliant sterile fill-finish syringes, sterile injectable compounding, FDA-shortlisted drugs, and bacteriostatic water for injection (BWFI) in multi-dose vials.

By maintaining a 100% domestic U.S. supply chain compliant with cGMP (21 CFR Parts 210–211), ISO 13485, USP <797>/<800>, TAA-compliant drug manufacturing, and Berry Amendment-compliant pharmaceuticals—plus full GSA/SAM registration for NAICS 325414, NAICS 325412, PSC 6505, and AI14 Defense R&D—MayMag Biologics eliminates overseas API dependencies for insulin and biosimilar insulin manufacturers in the USA.





Comments

Popular posts from this blog

MayMag Biologics formerly Tirzepatide Pharma Biopharmaceutical Compounding Industry For FDA Approved Sterile 506e Biologics

MayMag Biologics Corp Expands Domestic cGMP Co-Manufacturing Capacity in Texas to Support SAM.gov Federal Prime Contractors

Scalable industrial 506e offering high-volume pharmaceutical large-scale prescription manufacturing.